Dale L. Barnard Copyright (c) 2013 All rights reserved. http://works.bepress.com/dale_barnard Recent documents in Dale L. Barnard en-us Sun, 19 May 2013 01:39:12 PDT 3600 Evaluation of Immune Modulators, Interferons and Known In Vitro SARS-CoV Inhibitors for Inhibition of SARS-CoV Replication in BALB/c Mice http://works.bepress.com/dale_barnard/89 http://works.bepress.com/dale_barnard/89 Fri, 17 May 2013 10:56:34 PDT Compounds approved for therapeutic use and in vitro inhibitors of severe acute respiratory syndrome coronavirus (SARS-CoV) were evaluated for inhibition in the mouse SARS-CoV replication model. A hybrid interferon, interferon alpha (IFN-alpha) B/D, and a mismatched double-stranded (ds) RNA interferon (IFN) inducer, Ampligen (poly I:poly C124), were the only compounds that potently inhibited virus titres in the lungs of infected mice as assessed by CPE titration assays. When mice were dosed intraperitoneally (i.p.) with IFN-alpha B/D once daily for 3 days beginning 4 h after virus exposure, SARS-CoV replication in the lungs of infected mice was reduced by 1 log10 at 10,000 and 32,000 IU; at the highest dose of 100,000 IU, virus lung titres were below detectable limits. Ampligen used i.p. at 10 mg/kg 4 h prior to virus exposure also reduced virus lung titres to below detectable limits. Nelfinavir, beta-D-N4-hydroxycytidine, calpain inhibitor VI, 3-deazaneplanocin A and Alferon (human leukocyte IFN-alpha-n3) did not significantly reduce lung virus titres in mice. Anti-inflammatory agents, chloroquine, amodiaquin and pentoxifylline, were also inactive in vivo, suggesting that although they may be useful in ameliorating the hyperinflammatory response induced by the virus infection, they will not significantly reduce the replication of the virus, the inducer of inflammatory response. Thus, anti-inflammatory agents may only be useful in treating virus lung infections if used in combination with agents that inhibit virus replication. In summary, the data suggest that induction of IFN by mismatched dsRNA or actual treatment with exogenous IFN-alpha can inhibit SARS-CoV replication in the lungs of mice.

]]> Dale L. Barnard Influence of virus straight, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201 http://works.bepress.com/dale_barnard/88 http://works.bepress.com/dale_barnard/88 Fri, 12 Apr 2013 08:26:07 PDT R W. Sidwell et al. Progression of Aleutian mink disease in natural and experimental infections http://works.bepress.com/dale_barnard/87 http://works.bepress.com/dale_barnard/87 Fri, 12 Apr 2013 08:26:06 PDT M K. Jackson et al. Suitability of new chlamydia transport medium for transport of herpes simplex virus http://works.bepress.com/dale_barnard/86 http://works.bepress.com/dale_barnard/86 Mon, 23 Jan 2012 15:28:47 PST Dale L. Barnard et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo http://works.bepress.com/dale_barnard/85 http://works.bepress.com/dale_barnard/85 Mon, 23 Jan 2012 15:28:43 PST C. W. Day et al. Genvir http://works.bepress.com/dale_barnard/84 http://works.bepress.com/dale_barnard/84 Mon, 23 Jan 2012 15:28:39 PST Dale L. Barnard Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine http://works.bepress.com/dale_barnard/83 http://works.bepress.com/dale_barnard/83 Mon, 23 Jan 2012 15:28:35 PST D. F. Smee et al. Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus http://works.bepress.com/dale_barnard/82 http://works.bepress.com/dale_barnard/82 Mon, 23 Jan 2012 15:28:32 PST D. F. Smee et al. Aleutian Disease: How it is spread and possible treatments http://works.bepress.com/dale_barnard/81 http://works.bepress.com/dale_barnard/81 Mon, 23 Jan 2012 15:28:28 PST L. C. Ellis et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses http://works.bepress.com/dale_barnard/80 http://works.bepress.com/dale_barnard/80 Mon, 23 Jan 2012 15:28:25 PST Dale L. Barnard et al. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds http://works.bepress.com/dale_barnard/79 http://works.bepress.com/dale_barnard/79 Mon, 23 Jan 2012 15:28:21 PST D. F. Smee et al. In vitro influenza virus-inhibitory effects of a series of germanium- or silicon-centered polyoxometalates http://works.bepress.com/dale_barnard/78 http://works.bepress.com/dale_barnard/78 Mon, 23 Jan 2012 15:28:17 PST J. H. Huffman et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities http://works.bepress.com/dale_barnard/77 http://works.bepress.com/dale_barnard/77 Mon, 23 Jan 2012 15:28:13 PST D. F. Smee et al. Broad Spectrum in vitro Activity and in vivo Efficacy of the Antiviral Protein Griffithsin Against Emerging Viruses of the Family Coronaviridae http://works.bepress.com/dale_barnard/76 http://works.bepress.com/dale_barnard/76 Mon, 23 Jan 2012 15:28:09 PST B. R. O'Keefe et al. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes http://works.bepress.com/dale_barnard/75 http://works.bepress.com/dale_barnard/75 Mon, 23 Jan 2012 15:28:05 PST Dale L. Barnard et al. Antiviral activities of biflavonoids http://works.bepress.com/dale_barnard/74 http://works.bepress.com/dale_barnard/74 Mon, 23 Jan 2012 15:28:01 PST Y. M. Lin et al. Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP) http://works.bepress.com/dale_barnard/73 http://works.bepress.com/dale_barnard/73 Mon, 23 Jan 2012 15:27:57 PST J. P. Roth et al. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin on experimentally-induced Phlebovirus infections http://works.bepress.com/dale_barnard/72 http://works.bepress.com/dale_barnard/72 Mon, 23 Jan 2012 15:27:53 PST R. W. Sidwell et al. The effects of human cytomegalovirus (HCMV) inhibitory agent, 9-(3'-phosphono-1'-hydroxymethyl-1'- propyloxymethyl)guanine (SR3745), on macromolecular synthesis and in vitro antiviral activity in human diploid cells http://works.bepress.com/dale_barnard/71 http://works.bepress.com/dale_barnard/71 Mon, 23 Jan 2012 15:27:50 PST Dale L. Barnard et al. A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it http://works.bepress.com/dale_barnard/70 http://works.bepress.com/dale_barnard/70 Mon, 23 Jan 2012 15:27:46 PST W. F. Mangel et al.